Core Insights - Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for patients with solid tumors [3] - The company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, 2025 [1] Company Overview - Bicara Therapeutics is dedicated to creating transformative bifunctional therapies, with its lead program being ficerafusp alfa, a first-in-class bifunctional antibody [3] - Ficerafusp alfa targets the tumor microenvironment by combining an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β) [3] - The therapy aims to reverse the fibrotic and immune-excluded tumor microenvironment, facilitating deeper tumor penetration and promoting durable responses [3] - Ficerafusp alfa is currently being developed for head and neck squamous cell carcinoma and other solid tumor types, addressing significant unmet medical needs [3]

Core Points - Current Water Technologies Inc. has successfully closed a private placement raising a total of $209,450 CAD [1][2] - The company issued 6,981,667 units at a price of $0.03 per unit, with each unit consisting of one Common Share and one Share Purchase Warrant [2] - Each Warrant allows the holder to purchase one Common Share at an exercise price of $0.06, exercisable for three years from the closing date [2] Private Placement Details - The private placement was conducted under the minimum price exception within Policy 1.1 of the TSXV Corporate Manual, allowing issuance at the market price with a minimum of $0.01 [3] - No finder's fees were paid in connection with the private placement [2] - Gene Shelp, the CEO, participated in the private placement by acquiring 1,315,000 units and warrants, which are considered related party transactions [4] Insider Participation - The participation of insiders did not materially change the percentage of outstanding securities owned by them, and the company is exempt from formal valuation and minority shareholder approval requirements [4] - The common shares issued to insiders are subject to a four-month hold period as per TSX-V policies [4] Company Overview - Current Water Technologies is a technology company specializing in patented electrochemical technologies for wastewater treatment, desalination, and drinking water purification [5] - The company operates in sectors including mining, metal processing, chemical, agricultural, municipal, and waste management [5] - Pumptronics Incorporated, a division of the company, focuses on custom design and automation of integrated pump stations [5] Trading Information - The common shares of Current Water Technologies trade on Tier II of the TSX Venture Exchange under the symbol "WATR" [6]

Flight utilized BETA’s ALIA CTOL, which departed East Hampton Airport, New York and arrived at John F. Kennedy International Airport in New York CityBlade CEO Rob Wiesenthal's participation as a passenger on the all-electric flight underscores the company’s commitment to quiet, emission-free air mobilityBlade, BETA Technologies, and other Advanced Air Mobility manufacturers continue to collaborate on the integration of Electric Vertical Aircraft (“EVA” or “eVTOL”) in Blade’s service model NEW YORK, June 03, ...

Core Insights - Immix Biopharma's NXC-201 achieved a complete response (CR) rate of 70% in the NEXICART-2 Phase 1/2 clinical trial for relapsed/refractory AL Amyloidosis, meeting its primary endpoint [1][4][3] - The trial reported no relapses or safety signals to date, indicating a favorable safety profile for NXC-201 [1][4] - Immix plans to submit a Biologics License Application (BLA) to the FDA for NXC-201 following these promising results [1][3] Clinical Trial Details - The NEXICART-2 trial is a U.S. multi-site, single-arm study evaluating NXC-201 in patients with relapsed/refractory AL Amyloidosis, with a data cutoff of April 11, 2025 [1][3][7] - Prior to treatment, patients had a median of 4 lines of therapy, and all had organ involvement from the disease [4] - After treatment, all patients normalized pathological disease markers, with 70% achieving complete responses [4] Safety and Efficacy - No neurotoxicity was observed, and only low-grade cytokine release syndrome was reported [4][9] - The remaining 3 patients who did not achieve CR are minimum residual disease (MRD) negative, suggesting potential future CRs [4] Market Context - Current treatments for relapsed/refractory AL Amyloidosis have a CR rate of less than 10%, highlighting a significant unmet medical need [5] - The U.S. prevalence of relapsed/refractory AL Amyloidosis is estimated to grow at 12% per year, reaching approximately 33,277 patients by 2024 [11] - The amyloidosis market was valued at $3.6 billion in 2017 and is projected to reach $6 billion by 2025 [11] Company Overview - Immix Biopharma is a clinical-stage biopharmaceutical company focused on developing cell therapies for AL Amyloidosis and other serious diseases [12] - NXC-201 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Orphan Drug Designation from both the FDA and EMA [9][12]

Core Points - Colabor Group Inc. has completed the acquisition of food distribution assets from Alimplus Inc. and all shares of Tout-Prêt Inc. for a revised total consideration of $49.75 million [1] - The acquisition includes assets related to food distribution and the shares of Tout-Prêt, which specializes in cut fruits and vegetables distribution in Quebec, with expected annual sales of approximately $225 million [2] - Colabor has entered into a distribution agreement with Groupe Mayrand Alimentation inc. for an initial six-year term, although their four stores are not part of the acquisition [2] Financing Details - The company has amended and restated its senior first-ranking secured credit facility, extending the maturity date to June 2029, with a total amount of $91.75 million [5] - The credit facility consists of a $50 million revolving credit and a $41.75 million term loan [5] - Colabor has also secured an agreement with Investissement Québec to extend its existing $15 million subordinated debt maturing in December 2029 and entered into a new financing agreement for an additional $15 million in highly subordinated debt with a 5-year term [5]

Group 1 - EssilorLuxottica successfully launched a bond issuance totaling Euro 1 billion, maturing in January 2030, with a coupon of 2.625% and a yield of 2.76% [4] - The bond issuance attracted significant interest, with the order book peaking over Euro 2.5 billion, indicating strong confidence from institutional investors in EssilorLuxottica's business model and credit profile [4] - The proceeds from the bond issuance will be utilized for general corporate purposes, with trading on Euronext Paris expected to commence on June 10, 2025 [5] Group 2 - The bonds were offered exclusively to qualified investors as defined by MiFID II, and are not available to retail investors [2] - EssilorLuxottica holds ratings of A2 positive from Moody's and A stable from S&P, reflecting its solid creditworthiness [4]

Core Points - Biofrontera Inc. announced the inclusion of its propylene glycol-free formulation of Ameluz nanoemulsion gel in the FDA's Orange Book, confirming its FDA-approved status and intellectual property protection [1][2][7] - The revised formulation eliminates propylene glycol, a known allergen, enhancing patient safety while maintaining treatment efficacy [3][4] - The patent for the new formulation was issued on April 22, 2025, and is valid until December 8, 2043, preventing generic competition during this period [2][3][7] Company Overview - Biofrontera Inc. specializes in biopharmaceuticals, focusing on dermatological treatments using photodynamic therapy (PDT) [5] - The company commercializes Ameluz in combination with the RhodoLED lamp series for treating actinic keratosis and is conducting clinical trials for additional applications [5]

A nine-episode podcast — scripted and narrated using artificial intelligence — recaps the firm’s activity over the past yearTransformation, integration and sustainable growth were the Corporate Affairs and Marketing firm’s key pillars in 2024 MADRID, June 03, 2025 (GLOBE NEWSWIRE) -- LLYC (BME:LLYC) is embracing AI and synthetic voices for the launch of its 2024 Annual Report. Two AI-generated voices, IAn and MaIA, guide listeners through a nine-episode podcast summarizing the company’s year, showcasing its ...

3 June 2025 Orange: information on the total number of shares and voting rights referred to in Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. In application of Article L. 22-10-46 of the French Commercial Code (Code de commerce), as from 3 April 2016, a double voting right is automatically granted to fully paid-up shares that have been held in registered form and under a single shareholder name for at least two years. D ...

Company Overview - Sidetrade is a global leader in AI-powered Order-to-Cash applications, recently included in the 2025 Euronext Tech Leaders Index, which highlights high-growth tech companies in Europe [1][2] - The company has a market capitalization exceeding €300 million and has achieved a Compound Annual Growth Rate (CAGR) above 20% over the last three years [6] Technology and Innovation - Sidetrade's AI, named Aimie, is an autonomous agent designed to optimize cash flow processes by making decisions and adapting in real-time, utilizing a behavioral dataset of over $7.2 trillion in payment data [3][6] - Aimie enhances decision-making across a global network of over 40 million buyers, showcasing Sidetrade's commitment to innovation and intelligent orchestration in enterprise finance [3][4] Leadership and Vision - Olivier Novasque, the founder and CEO of Sidetrade, has been instrumental in the company's vision, advocating for a shift from automation to real-time intelligent orchestration in finance [4][5] - The company's approach emphasizes augmenting human capacity through technology, aiming to enhance judgment and accelerate actions in a complex financial landscape [5]